SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 189.93+0.5%Jan 2 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (13636)1/23/1998 1:45:00 AM
From: Henry Niman   of 32384
 
Here's the Dow Jones version of PRNewswire:

Pfizer Shifts Droloxifene Focus From Breast Cancer
Treatment

(MORE) DOW JONES NEWS 01-22-98

05:11 PM

NEW YORK (Dow Jones)--Pfizer Inc. (PFE) said due to interim clinical
trial results it is shifting the focus of its developmental program for
droloxifene, an estrogen agonist/antagonist, from treatment of advanced
breast cancer to prevention of osteoporosis.

In a press release Thursday, Pfizer said interim results from the clinical trial
of droloxifene for the treatment of advanced (metastatic)
estrogen-receptor-positive breast cancer showed that at the dose studied,
droloxifene offers no benefit beyond the current therapy.

Therefore, the company won't submit the droloxifene New Drug
Application for treatment of breast cancer in the fourth quarter of 1998 as
originally anticipated.

Pfizer said preliminary data on the efficacy and safety of droloxifene in
osteoporosis are encouraging, especially when compared to currently
available products, and Pfizer will now accelerate development efforts in
this therapeutic area.

The company also plans to investigate the use of droloxifene in the
prevention of breast cancer and other potential health issues of
post-menopausal women.

Separately, Pfizer has discontinued exploration of the anti-arthritic agent
tenidap for possible future development as a disease-modifying agent for
osteoarthritis. Future research will focus on back-up anti-arthritis
compounds with potentially enhanced safety and efficacy characteristics.

Also, Pfizer confirmed it will file an NDA with the Food and Drug
Administration for dofetilide in March. Dofetilide is a selective
potassium-channel blocker for the treatment of atrial fibrillation (AF).
Clinical data indicate dofetilide is effective in controlling AF, a type of heart
arrhythmia, and is better tolerated than older drugs.

Pfizer is a research-based healthcare company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News